those ex-FDA staffers has expertise in designing preclinical tests, not anything we would hear about
This is an important point which (IMO) ties with AVXL holding cards very close(ly).
My limited(<5 years) experience w/dev/use of AI in Tech showed my team how little we actually wanted to reveal b/c the AI driven learning processes-experience did very, very quickly bring us to an understanding of how some of our unknow-unknows would quickly bring us to paths of new learning which we would previously likely not even considered...long story...bottom line . The more you know , the more you(at least ) learn to appreciate all the other knowledge likely-obvious paths which you had previously not considered-thought about. It (AI USE) can quickly get complicated and the smarter/more insightful the team members the more complicated the needed research process becomes. In fact, the learning process links slow the entire normal cycle down while even the brightest thinkers in the room can become humbled. Letting new knowledge escape is the last thing we want.
A strange and unexpected outcome of AI is that it's use can/may actually result in slowing the research-learning processes down as all the possible previously unseen links begin to flower forth. IMO, some of that may have caused some of the best & brightest ex-fda team players to stop and recognize just how big the S1R link is and that any CNS (Emphasize SYSTEMS) knowledge needs to be carefully handled, else we give away the farm , inadvertently.
IMO, this is a legitimate dilemma that Dr.M and the leadership team must manage carefully. There is such a thing as being TOO FAR out over- in front of your skis.
Obviously, just an opinion-for our position , but I have seen such things happen in a previous high technology life ...it is possible to get too far out over your skis.
Market Data 
Markets 
AI
